Drug regulatory body bans import of medicines from 16 Indian companies
Publication of the list by the department, the national regulatory body of the drugs markets, both allopathic and ayurveda, means that medicines manufactured by those companies cannot be imported to Nepal.
“After inspection of the manufacturing facilities of the pharmaceutical companies, which had applied to export their products to our country, we have published the list of the companies that do not comply with the World Health Organisation’s good manufacturing practices,” said Santosh KC, a spokesperson at the department.
Good manufacturing practice is a system of ensuring that products are constantly produced and controlled according to the set quality standards. It is designed to minimise the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product.
In April and July, the department had sent a team of drug inspectors to India to probe the manufacturing facilities of pharmaceutical companies that had applied to supply their products to Nepal.
Among the companies the department prohibited from exporting pharmaceutical drugs to Nepal is the Haridwar-based Divya Pharmacy, a company promoted by Yoga Guru Baba Ramdev.
Alongside, the list includes Radiant Parenterals Ltd., Mercury Laboratories Ltd., Alliance Biotech, Captab Biotec, Aglowmed Limited, Zee Laboratories Ltd, Daffodils Pharmaceuticals Ltd,GLS pharma Limited, Unijules Life Science Ltd, Concept Pharmaceuticals Pvt, Shree Anand Life Sciences Ltd, IPCA laboratories Ltd, Cadila Healthcare Ltd, Dial Pharmaceuticals, Aglowmed Limited and Mackur laboratories Ltd.
The department said that, among the Indian companies it has prohibited, some are already registered and some are new. Products of some companies do not comply with the regulatory requirements and some companies do not comply with good manufacturing practices. Among them, some companies’ products are used in critical care, dental cartridges and also vaccines.
The department has also published a list of 46 drug manufacturing companies, which are found to comply with the World Health Organisation’s good manufacturing practices.
Inspecting good manufacturing practices of pharmaceutical companies—both national and foreign—is a regular duty of the department.
A few months ago, the department had alerted drug inspectors to step up surveillance to prevent the import and sales of cough syrups manufactured by an Indian pharmaceutical company after scores of children in Gambia died of kidney failure upon allegedly consuming the syrups.
The department’s move follows a global alert by the World Health Organisation about four cough syrups that could have links to the deaths of the children in July, August, and September in the West African country.